Navigation Links
New Data from Silence's Atu027 Anticancer Trial Published at ASCO
Date:5/16/2012

LONDON, May 17, 2012 /PRNewswire/ --

- Atu027, a First in Class RNAi Therapy, Demonstrates Potential

- Antitumour Activity in Cancer Patients and Possible Biomarker Identified

Silence Therapeutics to Announce New Data from Phase I Study of Atu027 in Solid Tumours At 2012 ASCO Annual Meeting

Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, today announces that top line data from its ongoing Phase I trial of Atu027 show that of the 33 patients treated in the first 10 cohorts of the study, 10 patients experienced stable disease after three months. Two patients with neuroendocrine cancers had disease stabilisation for nine and 12 months respectively, including partial regression of liver metastases in one patient. Another patient with breast cancer demonstrated regression of liver metastases. Importantly, among various biomarkers tested, sVEGFR-1 plasma levels decreased significantly upon treatment further confirming a potential biological effect of Atu027.  

Silence will publish the latest data from its ongoing Phase I study of Atu027, its lead internal therapeutics candidate, at the 2012 American Society of Clinical Oncology ("ASCO") Annual Meeting in Chicago, Illinois, 1-5 June 2012. Further data from the ongoing Phase I Atu027 clinical study will also be the subject of a presentation with the following details:

Abstract Title: Anti-metastatic activity of Atu027, a liposomal small interfering RNA formulation, targeting protein kinase N3 (PKN3): Final results of a phase I study in patients with advanced solid tumours. Abstract #: 98347 Presentation Date/Time: Mon, June 04, 2012 / 16:00 - 18:00 Location: Networking Lounge, Level 3, North Presenters: Klaus Giese [http://silence-therapeutics.com/about-us/man
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Silence Therapeutics Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting
2. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
3. Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Small Cell Lung Cancer
4. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
5. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
6. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
7. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
8. NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update
9. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
10. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
11. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... support to healthcare providers for behavioral health and ... secured $30 million in equity financing from new ... Drosos , President and Chief Executive Officer. ... and development of Assurex Health,s GeneSight ® ...
(Date:12/24/2014)... 2014 In response to urgent requests from the Deputy ... Sierra Leone , Direct Relief delivered two 10-bed medical ... treatment of local health workers who contract Ebola while fighting ... care center was constructed for foreign health care workers who ... for local Sierra Leonean health workers. With ...
(Date:12/22/2014)... Mass. , Dec. 22, 2014 ... leading manufacturer of innovative dialysis products, announced today ... has cleared its System One™ to perform hemodialysis ... known as home nocturnal hemodialysis. NxStage,s® System One ... by the FDA for this indication. ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3
... Switzerland, Jan. 9 ESBATech AG, a leading developer ... of the Phase I/IIa clinical development of its ... This double-blind, randomized, placebo-controlled Phase I/IIa clinical study ... efficacy on pain with ESBA105 applied locally via ...
... transplantation to be Quark,s second indication with ... Calif., Jan. 8 Quark Pharmaceuticals, Inc., ... novel RNA interference (RNAi)-based therapeutics, today announced ... its Phase I/II clinical trial evaluating its ...
Cached Medicine Technology:ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 2ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 3ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 4Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function 2Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function 3Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function 4
(Date:12/25/2014)... December 25, 2014 Recently, BellasDress ... on all its wedding dresses. BellasDress has chosen their ... for gift choices for the holiday season. , ... pick suitable wedding gowns here at discount prices. The ... experience at its website. , “All our ...
(Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International ... after an 8 year battle with breast cancer. ... in her home in Woodland Hills California after an ... , As the founder and volunteer President ... and championed many of today's greatest breakthroughs in restoring ...
(Date:12/25/2014)... 25, 2014 Recently, LunaDress.co.uk has updated its blog ... related accessories. Now, all of the models at LunaDress.co.uk come with ... groom lifts the wedding veil can turn out to be a ... A wedding veil can always bring surprise to a wedding. On ... how to choose veils for a big day . , ...
(Date:12/25/2014)... (HealthDay News) -- The risk of burns from fires ... need to be extra cautious, an expert says. ... significant increase in patients coming in with burns," said ... Volunteer Firefighters Burn Center of Stony Brook University Hospital ... of joy, but if not careful, could quickly turn ...
(Date:12/25/2014)... News) -- Among early stage breast cancer patients who ... one percent will eventually develop leukemia as a result ... finding comes from a review of more than 20,000 ... it suggests that the risk for developing treatment-related leukemia, ... thought. "The frequency of bone marrow cancers such ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... offers formulas of essential prenatal ... ... Mission Pharmacal today announced,the launch of the CitraNatal(TM) family of ... of essential vitamins,and minerals for women prior to conception, throughout ...
... an,entrepreneur trained in Pilates, is bringing the latest Pilates ... Element Pilates.,Ilitch,s version of the innovative barre workout is ... and dance exercises,in rapid sequence to tone and transform ... any other studios in the area. According to ...
... on Cold and ... ... a division of,American Scientific Resources (Pink Sheets: ASFX), today announced the,launch ... world, now available at Walgreens Stores,nationwide and online at http://www.kidzmed.com ...
... health care system is one of only five organizations ... DIEGO, Nov. 20 President,George W. Bush and Commerce ... five organizations to receive the 2007 Malcolm,Baldrige National Quality ... performance excellence. (Photo: http://www.newscom.com/cgi-bin/prnh/20071120/DC07985-a ...
... Jewelers returns to national campaign for fourth year to support ... in communities everywhere., AKRON, Ohio, Nov. 20 Kay ... off its annual Thanks and Giving,campaign. This is the fourth ... has partnered with St. Jude in fundraising campaigns. Thanks ...
... Eularis WHAT: Presentation on Marketing Return: What can be ... WHEN: 26 November 2007 at 2:30 p.m. GMT, WHERE: Pharmaceutical ... ... and LONDON, Nov. 20 Dr. Andree Bates,president of the pharmaceutical analytics company ...
Cached Medicine News:Health News:Mission Pharmacal Launches CitraNatal(TM) Prescription Prenatal Vitamin Line 2Health News:Ilitch Brings New Brand of Pilates to Metro Detroit With Opening of Studio in West Bloomfield 2Health News:Ilitch Brings New Brand of Pilates to Metro Detroit With Opening of Studio in West Bloomfield 3Health News:World's First Non-Contact Thermometer for Children Now Available at Walgreens Nationwide 2Health News:World's First Non-Contact Thermometer for Children Now Available at Walgreens Nationwide 3Health News:Sharp HealthCare Receives 2007 Presidential Award for Quality and Performance Excellence 2Health News:Sharp HealthCare Receives 2007 Presidential Award for Quality and Performance Excellence 3Health News:Kay Jewelers Joins St. Jude Children's Research Hospital(R) to Kick Off Fourth Annual Thanks and Giving(R) Campaign 2Health News:Kay Jewelers Joins St. Jude Children's Research Hospital(R) to Kick Off Fourth Annual Thanks and Giving(R) Campaign 3Health News:MEDIA ALERT: Eularis to Address Marketing Return at Pharmaceutical Marketing Society Half-day Conference: ROI or RIP? 2
MISTY OX® Gas Injection Nebulizer (GIN)...
... OMNI~NEB delivers breakthrough continuous low-flow ... and precise nozzle technology allows for ... with or without Heliox). OMNI~NEB takes ... in both routine and critical care ...
... Raindrop® medication nebulizer achieves optimum lung penetration ... size range is 1.04-1.10 µ at 6-8 ... air outlet., ,As the world leader ... providers the assurance of proven technology by ...
Reliable and Affordable. The Schuco 3000 Nebulizer by Allied has been designed to offer a compact style that provides worry-free affordable nebulizer therapy....
Medicine Products: